Pedro Valencia, VP, asset strategy leadership, oncology, AbbVie, discusses how early data from ABBV-706 shows up to 50% ...

Small cell lung cancer is aggressive and spreads quickly. There are many options for treatment, depending on the type and ...

Pedro Valencia, VP, asset strategy, leadership, oncology, AbbVie, outlines how the company is accelerating development across ...

A rare cell in the lining of lungs is fundamental to the organ-wide response necessary to repair damage from toxins like ...

ABBV-706 is an ADC targeting SEZ6 developed by AbbVie. It is linked to a topoisomerase 1 inhibitor (TOP1i) via a ...

The positive CHMP opinion is based on data from the CABINET Phase III trial, which investigated Cabometyx versus placebo in people living with advanced pNETs or epNETs, whose disease had progressed ...

Cancers. 2022, 14 (19), 4769. 10 Frilling et al. Neuroendocrine tumor disease: an evolving landscape. 2012. 19:R163-R185 11 Survival Rates for Gastrointestinal Carcinoid Tumors. ACS website.

"I was told the cancer had spread and that I'd be referred to The Christie to see a specialist," Ms Lonergan continued. She ...

Here, the authors discover that FOXA2, regulated by ASCL1, promotes multi-site metastasis in small cell lung cancer by inducing a fetal neuroendocrine gene expression program.

Though biomarker testing isn’t routinely performed for SCLC, certain cases—such as never-smokers or large-cell neuroendocrine lung cancer patients—may benefit from genomic analysis.